Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. — KP-CARAIBES  

Neoplasm Metastasis Clinical Trial

Official title: Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.

Status Recruiting

Clinical Trial Summary

The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .

Clinical Trial Description

There is a lack of information to predict the course of prostate cancer following its initial diagnosis; in other words, why some are indolent and evolve very slowly and others are aggressive, evolve rapidly with an increased risk of metastasis development and death. In addition, these evolutions do not seem similar according to ethno-geographic origins. We therefore hypothesize that in addition to genetic susceptibility factors specific to individuals and / or linked to their ethno-geographic origins, medical, occupational and environmental factors can influence the course of the disease and the response to treatments. We will build two prospective cohorts of incident cases of prostate cancer, one in Guadeloupe (whose population is predominantly Afro-descendant) and one in Rennes (Brittany, whose population is mainly of Caucasian origin). Each patient will be subject to longitudinal follow-up over time. Structured questionnaires will be administered at the time of diagnosis and at regular times after the initial treatment or subsequent treatments. They will focus on socio-demographic data, places of residence, education levels, lifestyles (tobacco, alcohol), personal and family medical history, current treatments, current and past occupational activities. Anthropometric and blood pressure measurements will be made at the time of diagnosis and at regular times after treatment. Saliva, urine and blood samples will be obtained. Clinical data related to the disease will be collected continuously. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Disease Progression
• Neoplasm Metastasis
• Neoplasm Recurrence
• Neoplasms
• Prostatic Neoplasm
• Prostatic Neoplasms
• Recurrence

• NCT number: NCT06046131
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Pointe-a-Pitre
• Contact: Valérie HAMONY-SOTER
• Phone: +590 590 93 46 77
• Email: valerie.soter@chu-guadeloupe.fr
• Status: Recruiting
• Phase: N/A
• Start date: February 28, 2023
• Completion date: February 28, 2039